DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

Diffuse Large B-Cell Lymphoma Clinical Trial

— DLBCL  

Official title:

DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02815397
• Other study ID #: LYM15 DA-EPOCH-RM
• Status: Terminated
• Phase: Phase 2
• First received: May 17, 2016
• Last updated: October 17, 2017
• Start date: February 2016
• Est. completion date: July 2016

Study information

• Verified date: December 2016
• Source: Rush University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Newly diagnosed histologically confirmed c-myc+ de novo DLBCL. Metformin 500 mg daily x 1 week, then 500 mg twice daily (BID) x 2 weeks, then 850 mg twice daily until 1 month after last cycle of chemo-immunotherapy.

DA-EPOCH-R every 21 days x 4 cycles (CNS prophylaxis single or triple therapy given intrathecally each cycle to patients deemed appropriate by treating physician).

Restage after 4 cycles with CT. Complete remission or partial remission: complete 2 more cycles or radiation therapy (XRT) consolidation per physician. Stable or progressive disease will go on to salvage therapy off study.

Description:

Subject admitted to in-patient care for day 1 or each cycle and discharged on day 5. On day 6, subject receives Rituximab in outpatient infusion facility.

Metformin is dispensed on day 1 of each cycle and taken as follows: Cycle 1 days 1-7 500 mg daily. Days 8-21, 500 mg twice daily. Cycle 2 through end of treatment, metformin given 850 mg twice daily.

Inpatient treatment: DA-EPOCH every 21 days Etoposide (VP-16) 50 mg/m2/d civi d1-4 (continuous infusion) Prednisone 60 mg/m2 BID po d1-5 Vincristine 0.4 mg/m2/d civi d 1-4 (continuous infusion) Doxorubicin (Adriamycin) 10 mg/m2/d civi d1-4 (continuous infusion) Cyclophosphamide (Cytoxan) 750 mg/m2 IV over 15 min d5 If clinically indicated, patients who are deemed appropriate for central nervous system (CNS) prophylaxis by their treating physician will receive either single agent intrathecal methotrexate (12 mg) or triple therapy (15 mg methotrexate, 30 mg cytarabine, 30 mg hydrocortisone) with each cycle of chemotherapy.

Rituximab 375 mg/m2 IV every 21 days on D6-8 post DA-EPOCH (per standard institutional guidelines) DA-dose adjustment paradigm based on twice weekly complete blood count (CBC) (dose adjustment above starting doses apply to Etoposide (VP-16), Doxorubicin (Adriamycin) and Cyclophosphamide (Cytoxan). If nadir absolute neutrophil count(ANC)>500/microliter (uL), 20% increase in all 3 drugs. If nadir<500/uL on 1 or 2 measurements, same doses as last cycle. If nadir <500/uL on at least 3 measurements, or nadir platelet <25,000/uL on 1 measurement, 20% decrease in Etoposide, Doxorubicin and Cyclophosphamide below last cycle.

Filgrastim (Neupogen) 5 mcg/kg sc qd beginning on d6 until ANC>5,000/uL or Pegfilgrastim (Neulasta) 6 mg sc 24-72 hours post chemotherapy.

Restaging with CT scans is done after cycle 4 and:

complete remission (CR)/partial remission (PR) - complete 2 more cycles of therapy OR consolidation radiation therapy per treating physician.

stable disease (SD)/progressive disease (PD) - salvage therapy off study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female = 18 years of age

• Diagnosis of DLBCL as documented by medical records and with histology based on criteria established by the World Health Organization

• subtyping is required for DLBCL

• c-myc+ defined as presence of c-myc breaks by karyotype/FISH and/or IHC = 40%; this includes double hits (with bcl-2 breaks found using cytogenetics/FISH) and/or double expressors (with bcl-2 protein expression = 70% by IHC); increased copy number in itself is not considered positivity for c-myc

• No prior therapy for diagnosis of DLBCL with exception of steroids

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2 (Appendix B)

• Life expectancy of at least 6 months

• No history of medication dependent diabetes mellitus

• No evidence of acute or chronic metabolic acidosis (baseline venous lactate = 4)

Exclusion Criteria

• Patient already on any class of anti-diabetic medication including metformin, insulin analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies or clear need for therapeutic intervention based on fasting blood glucose

• Known histological transformation from indolent non-Hodgkin Lymphoma (iNHL) or chronic lymphocytic leukemia (CLL) to an aggressive form of non-Hodgkin's lymphoma (NHL) (ie, Richter transformation)

• Burkitt and/or precursor lymphoblastic leukemia/lymphoma.

• Presence of known intermediate- or high-grade myelodysplastic syndrome

• History of an active of treated non-lymphoid malignancy within the last 3 years excluding basal cell and squamous cell skin cancers

• Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug.

• Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)

• Renal insufficiency with creatinine > 1.5 x upper limit of normal (ULN) OR creatinine clearance of < 45 ml/min as calculated by the Cockcroft-Gault method

• CNS or leptomeningeal involvement of lymphoma

• HIV positive

• Ongoing inflammatory bowel disease

• Ongoing alcohol or drug addiction

• Pregnancy or breastfeeding

• History of prior allogeneic bone marrow progenitor cell or solid organ transplantation -

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• Metformin
given in addition to standard of care treatment

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Rush University Medical Center	Elsa U. Pardee Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of Impact of Metformin on 18 Month Progression-free Survival	Progression-free survival determined by CT scans at 18 months	18 month
Secondary	Effect of Metformin Overall Response Rate	Evaluation of the effect of the addition of metformin to induction chemotherapy on overall response rates	3 years
Secondary	Effect of Metformin Overall Survival	Evaluation of the addition of metformin to standard induction therapy on 18 month overall survival	18 months
Secondary	Safety Profile With Addition of Metformin Evaluated by Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0	Describe the safety profile observed by measuring fasting glucose and anion gap weekly through cycle 6.	18 months